Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AcousTx' portable ultrasound device finds and heals internal bleeds:

This article was originally published in Clinica

Executive Summary

US firm AcousTx is developing for use by the military a portable, automated ultrasonic cuff that will be able to locate sites of internal bleeding and then coagulate them in emergency situations. The device, for use by untrained soldiers on the battlefield, aims to stop bleeding quickly, in order to prevent the onset of progressive shock, "when a soldier loses 25% of his or her blood volume", said the firm. The cuff contains "multiple ultrasound transducer subarrays" that are wrapped around the treatment area. The device then scans the area for the internal bleed using a Doppler signal. Once located, high intensity ultrasound is used to coagulate it. AcousTx, based in Seattle, Washington, is a spin-out of ultrasound company Therus.

You may also be interested in...

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Horizon's Teprotumumab Breezes Through US FDA Adcom, But Safety Questions Remain

Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts